

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number  
**WO 2005/040133 A1**

(51) International Patent Classification<sup>7</sup>: C07D 239/42,  
401/04, A61K 31/505, 31/506

(21) International Application Number:  
PCT/IB2004/003314

(22) International Filing Date: 11 October 2004 (11.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/513,770 23 October 2003 (23.10.2003) US

(71) Applicant (for all designated States except US): PHAR-  
MACIA CORPORATION [US/US]; 700 Chesterfield  
Parkway West, Chesterfield, MO 63017-1732 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CLARE, Michael  
[US/US]; Pfizer Global Research and Development, 700  
Chesterfield Parkway West, Chesterfield, MO 63017-1732  
(US). HAGEN, Timothy, J. [US/US]; Pfizer Global Re-  
search and Development, 28 Plymouth Road, Ann Arbor,  
MI 48105 (US). HOUDEK, Stephen, C. [US/US]; Pfizer  
Global Research and Development, 700 Chesterfield Park-  
way West, Chesterfield, MO 63017-1732 (US). LENNON,  
Patrick, J. [US/US]; Pfizer Global Research and Devel-  
opment, 700 Chesterfield Parkway West, Chesterfield, MO  
63017-1732 (US). WEIER, Richard, M. [US/US]; Pfizer

Global Research and Development, 700 Chesterfield Park-  
way West, Chesterfield, MO 63017-1732 (US). XU, Xi-  
angdong [CN/US]; Pfizer Global Research and Develop-  
ment, 700 Chesterfield Parkway West, Chesterfield, MO  
63017-1732 (US).

(74) Agents: FULLER, Grover, F., Jr. et al.; Pfizer Inc., P.O.  
Box 1027, St. Louis, MO 63006 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



WO 2005/040133 A1

(54) Title: PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION



(1)

(57) Abstract: Compounds of Formula (I): wherein A, X, R<sup>2</sup> and R<sup>4</sup> are as defined herein, are dis-  
closed.

EXPRESS MAIL NO. EV770921844 US